← ANALYST RATINGS · TIPRANKS
Perrigo Company (PRGO): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months · top analysts only12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $17.00, the highest $17.00, the lowest $17.00. The average is +2.2% from the last price of $16.63.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi Drug Manufacturers - Specialty and GenericxAI Grok-3 | TipRanks - xAI | $15.50 → $16.50+6.5% | Hold | −0.8% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI DeepSeek Drug Manufacturers - Specialty and GenericDeepSeek R1-0528 | TipRanks - DeepSeek | $16.00 → $17.00+6.2% | Hold | +2.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI OpenAI Drug Manufacturers - Specialty and GenericOpenAI 4o | TipRanks - OpenAI | $15.50 → $17.00+9.7% | Hold | +2.2% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI Anthropic Drug Manufacturers - Specialty and GenericAnthropic Opus-4.1 | TipRanks - Anthropic | $15.00 → $16.00+6.7% | Hold | −3.8% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI Google Drug Manufacturers - Specialty and GenericGemini 2.5Pro | TipRanks - Google | $15.00 → $16.00+6.7% | Hold | −3.8% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| AI PerPlexity Drug Manufacturers - Specialty and GenericPerPlexity SonarPro | TipRanks - PerPlexity | $15.00 → $16.00+6.7% | Hold | −3.8% | Reiterated | 17.10.26on TipRanks Oct 16 23:06 | — | |
| Susan Anderson★★★★★★★★★★#576 · hits 45% · avg +16.7% | Canaccord Genuity | $17.00 | Buy | +2.2% | Reiterated | 12.08.26on TipRanks Aug 13 08:40 | −1.5%next day +0.4% · 5 days +10.5% | ↗ |
| Christine Dooley★★★★★★★★★★#2411 · hits 72% · avg +16.0% | Argus Research | — | Hold | — | Reiterated | 19.05.26on TipRanks May 25 05:15 | 0.0%next day +4.2% · 5 days +2.9% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $57.00 → $15.00−73.7% | Hold | −9.8% | Reiterated | 27.02.26on TipRanks 08:01 | −6.4%next day −4.6% · 5 days −15.1% | ↗ |
| Keith Devas★★★★★★★★★★#11126 · hits 14% · avg −11.8% | Jefferies | $27.00 → $23.00−14.8% | Hold | +38.3% | Reiterated | 27.10.25on TipRanks 07:25 | +1.1%next day −1.8% · 5 days −6.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Perrigo Company
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $17.00 at a price of $14.76 (+15.2%); now: $17.00 at $16.63 (+2.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 1 | 1 | 1 | 0 | 0 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.52 (from $0.47 to $0.55). Last quarter: $0.50.
Sales
Next quarter’s sales estimate — $992M (from $990M to $993M). Last quarter: $1.0B.
Best top-analyst consensus in the sector · Healthcare
About Perrigo Company
- CEO: Albert A. Manzone
- Employees: 8,100
- The Sharp Building, Dublin, DU, D02 TY74, IE
- www.perrigo.com
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Data from the stock’s TipRanks forecast page, read 135 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗